1. Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma
by Paul M. Barr, Thomas P. Miller, Jonathan W. Friedberg, Derick R. Peterson, Andrea M. Baran, Megan Herr, Catherine M. Spier, Haiyan Cui, Denise J. Roe, Daniel O. Persky, Carla Casulo, Jamie Littleton, Mark Schwartz, Soham Puvvada, Terry H. Landowski, Lisa M. Rimsza, Robert T. Dorr, Richard I. Fisher, Steven H. Bernstein, and Margaret M. Briehl
Blood
Volume 124(8):
August 21, 2014
©2014 by American Society of Hematology

2. Progression-free survival.
Progression-free survival. In (A) all patients and (B) patients with FL.
Paul M. Barr et al. Blood 2014;124:
©2014 by American Society of Hematology

3. Correlation of redox signature score with response category.
Correlation of redox signature score with response category. Correlation = −0.59. PD, progression of disease.
Paul M. Barr et al. Blood 2014;124:
©2014 by American Society of Hematology